Factors associated with the author-reported cost-effectiveness threshold in high-income countries: systematic review and multivariable modelling.
| dc.rights.license | open | en_US |
| dc.contributor.author | BOESPFLUG, Nicolas | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | WITTWER, Jerome | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | BENARD, Antoine | |
| dc.date.accessioned | 2023-10-17T09:50:25Z | |
| dc.date.available | 2023-10-17T09:50:25Z | |
| dc.date.issued | 2023-07-11 | |
| dc.identifier.issn | 1618-7601 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/184457 | |
| dc.description.abstractEn | The cost-effectiveness threshold (CET) is a key parameter to guide objective reimbursement decisions, yet very few countries have defined a reference CET, and there is no reference method for defining it. Our objective was to determine the factors explaining the author-reported CETs in the literature. Our systematic review targeted original articles referenced in EMBASE and published between 2010 and 2021. Selected studies had to use Quality-Adjusted Life-Year (QALY), and being conducted in high-income countries. Our explanatory variables were: estimated cost-effectiveness ratio (ICER), region of the world, source of funding, type of intervention, disease, year of publication, justification of the author-reported Cost-Effectiveness Threshold (ar-CET), economic perspective, and declaration of interest. Multivariable linear regression models implemented on R software were used, guided by a Directed Acyclic Graph. Two hundred and fifty four studies were included. The mean ar-CET was €63,338/QALY (standard deviation (SD) 34,965) overall, and €37,748/QALY (SD 20,750) in studies conducted in the British Commonwealth. The ar-CET increased slightly with the ICER (+ 66€/QALY for each additional 10,000€/QALY in the ICER, 95% confidence interval (IC) [31-102], p < 0.001), was higher in the United States (+ 36,225€/QALY; IC [25,582; 46,869]) and Europe (+ 10,352€/QALY; IC [72; 20,631]) compared to the British Commonwealth (p < 0.001), and was higher when the ar-CET was not defined a priori (+ 22,393€/QALY; [5809; 38,876]) compared to state recommendations defined ar-CET (p < 0.001). Our results underline the virtuous role of state recommendations in the choice of a low and homogeneous CET. We also highlight the need to integrate the a priori justification of the CET into good publishing guidelines. | |
| dc.language.iso | EN | en_US |
| dc.subject.en | Cost-effectiveness analyses | |
| dc.subject.en | Cost-effectiveness threshold | |
| dc.subject.en | Drugs | |
| dc.subject.en | Medical devices | |
| dc.subject.en | Multivariable modelling | |
| dc.subject.en | Systematic review | |
| dc.title.en | Factors associated with the author-reported cost-effectiveness threshold in high-income countries: systematic review and multivariable modelling. | |
| dc.title.en | Factors associated with the author-reported cost-effectiveness threshold in high-income countries: systematic review and multivariable modelling | |
| dc.title.alternative | Eur J Health Econ | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1007/s10198-023-01613-7 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 37433889 | en_US |
| bordeaux.journal | European Journal of Health Economics | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | PHARES | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.import.source | pubmed | |
| hal.identifier | hal-04245819 | |
| hal.version | 1 | |
| hal.date.transferred | 2023-10-17T09:50:27Z | |
| hal.popular | non | en_US |
| hal.audience | Internationale | en_US |
| hal.export | true | |
| workflow.import.source | pubmed | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=European%20Journal%20of%20Health%20Economics&rft.date=2023-07-11&rft.eissn=1618-7601&rft.issn=1618-7601&rft.au=BOESPFLUG,%20Nicolas&WITTWER,%20Jerome&BENARD,%20Antoine&rft.genre=article |
Fichier(s) constituant ce document
| Fichiers | Taille | Format | Vue |
|---|---|---|---|
|
Il n'y a pas de fichiers associés à ce document. |
|||